G.B. DIKKE

Russian University of Friendship of Peoples, 6 Miklukho-Maklaya Str., Moscow, Russian Federation, 117198

 Dikke G.B. ― D. Med. Sc., Professor of the Department of Obstetrics, Gynecology and Reproductive Medicine, tel. +7-926-528-03-83, e-mail: galadikke@yandex.ru

 The review is dedicated to modern ways of improving the quality of medical aid to women in the need of early termination of pregnancy. The article presents data relating to broadening indicators for the use of medicamentous method, as well as the period of pregnancy termination. Optimal doses of mifepriston, doses and regime of misoprostol are described. The termination of incomplete spontaneous or induced abortion is considered, as well as the uterus emptying during the missed abortion and pregnancy termination at late periods. The author believes that the medicamentous method of early pregnancy termination has its advantages and should replace the surgical ones.

Key words: pregnancy termination, medicamentous abortion, mifepriston, misoprostol.

REFERENCES

1. Royal College of Obstetricians and Gynaecologists (RCOG). The care of women requesting induced abortion. London (England): Royal College of Obstetricians and Gynaecologists (RCOG); 2011 Nov. 130 p. (Evidence-based Clinical Guideline; no. 7), available at: http://www.rcog.org.uk
2. American College of Obstetricians and Gynaecologists (ACOG). A Clinician’s Guide to Medical and Surgical Abortion, NAF’s textbook, 2012, available at: http://www.prochoice.org
3. Safe abortion: technical and policy guidance for health systems Second edition Share Print. World Health Organization, Department of Reproductive Health and Research. WHO, 2012, available at: http://www.who.int/
4. Ancel P.Y., Lelong N., Papiernik E., Saurel-Cubizolles M.J., Kaminski M. EUROPOP. History of induced abortion as a risk factor for preterm birth in European countries: results of the EUROPOP survey. Hum Reprod. 2004;19(3):734–40.
5. Shah P.S., Zao J. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analysis. BJOG, 2009;116:1425–1442.
6. Swingle H.M., Colaizy T.T., Zimmerman M.B, Morriss F.H. Abortion and the risk of subsequent preterm birth: A systematic review with meta-analyses. J Rrepro Med., 2009;54:95-108.
7. World Health Organization. Safe abortion: Technical and policy guidance for health systems. Geneva, The World Health Organization; 2003.
8. Kulier R., Kapp N., Metin Gülmezoglu A., Justus Hofmeyr G., Linan Chen5, Aldo Campana. Medical methods for first trimester abortion, 2011, available at: http://summaries.cochrane.org
9. Allen R., O’Brien B.M. Uses of Misoprostol in Obstetrics and Gynecology. Rev Obstet Gynecol., 2009; 2(3): 159–168.
10. Raymond E.G., Shannon C., Weaver M.A., Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: A systematic review. Contraception. 2013; 87(1): 26–37.
11. Belokrinitskaya T.E., Frolova N.I., Belokrinitskaya I.A., Sukhinina V.V. A comparative assessment of the clinical course of medical abortion performed with 200 and 600 mg of mifepristone: a prospective cohort study. Akusherstvo i ginekologiya. 2014; 3: 80–85 (in Russ.).
12. Plotko E.E. Prognozirovanie, profilaktika, diagnostika i lechenie oslozhneniy iskusstvennogo preryvaniya beremennosti: avtoref. dis. d-ra med. nauk [Forecasting, prevention, diagnosis and treatment of complications of artificial termination of pregnancy. Synopsis of dis. Dr med. sciences]. Moscow, 2013.
13. Grossman D. Medikamentoznye metody provedeniya aborta v pervom trimestre: Kommentariy BRZ (poslednyaya redaktsiya: 3 sentyabrya 2003 g.). Biblioteka reproduktivnogo zdorov’ya VOZ [Medical methods of abortion in the first trimester: RHL commentary (last revised: September 3, 2003). The WHO Reproductive Health Library]. Zheneva: Vsemirnaya organizatsiya zdravookhraneniya.
14. Aubeny E. A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins. Eur J Contracept Reprod Health Care, 2001;6:54–5.
15. Gallo M.F., Cahill S., Castleman L., Mitchell E.M.H. A systematic review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks of gestation. Sontraception, 2006;74:36–41.
16. Boersma A.A., Jong M.B., Kleiverda G. Mifepriston followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a genital practice in Curaçao. Europ. J. Contracep. Repr. Health Care, 2011; 16:61–66.
17. Winikoff B., Dzuba I.G., Chong E, Goldberg A.B., Lichtenberg E.S., Ball C., Dean G., Sacks D., Crowden W.A., Swica Y. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol., 2012;120(5):1070–6.
18. Chong E., Tsereteli T., Nguyen N.N., Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception. 2012;86(3):251–6.
19. Bracken H., Dabash R., Tsertsvadze G. et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective comparative open-label trial. Contraception. 2014;89(3):181-6.
20. WHO. Model list of essential medicines. 18th ed. Geneva: WHO, 2013, available at: http://mednet3.who.int/EMLib/
21. Neilson J.P., Gyte G.M., Hickey M., Vazquez C., Dou L. Medical treatments for incomplete miscarriage (less than 24 weeks). Cochrane Database of Systematic Reviews. 2010.
22. RCOG. Ectopic pregnancy and miscarriage. Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. Issued: December 2012. NICE clinical guideline 154.
23. MISOPROSTOL. FIGO. Posologie recommandée. 2012, available at: www.figo.org.
24. Diop A., Raghavan S., Rakotovao J.P., Comendant R., Blumenthal P.D., Winikoff B. Two routes of administration for misoprostol in the treatment of incomplete abortion: a randomized clinical trial. Contraception. 2009;79(6):456–62.
25. Fawole A.O., Diop A., Adeyanju A.O., Aremu O.T., Winikoff B. Misoprostol as first-line treatment for incomplete abortion at a secondary-level health facility in Nigeria. Int J Gynaecol Obstet. 2012;119(2):170–3.
26. Montesinos R., Durocher J., León W., Arellano M., Peña M., Pinto E., Winikoff B. Oral misoprostol for the management of incomplete abortion in Ecuador. Int J Gynaecol Obstet., 2011;115(2):135–9.
27. Klingberg-Allvin M., Cleeve A., Atuhairwe S., Tumwesigye N.M., Faxelid E., Byamugisha J., Gemzell-Danielsson K. Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet, 2015 Mar 26S0140-6736(14)61935–8.
28. Adisso S., Hounkpatin B.I., Komongui G.D., Sambieni O., Perrin R.X. Introduction of misoprostol for the treatment of incomplete abortion beyond 12 weeks of pregnancy in Benin. Int J Gynaecol Obstet. 2014;126(1):36–9.
29. Bhadra B., Deb T. Role of oral misoprostol for treatment of incomplete abortion. Journal of the Indian Medical Association, 2013, 111(10):689–691.
30. Zeqiri F., Paçarada M., Kongjeli N., Zeqiri V., Kongjeli G. Missed abortion and application of misoprostol. Med Arh., 2010;64(3):151–3.
31. Gemzell-Danielsson K., Ho P.C., Gómez Ponce de Le ón R., Weeks A., Winikoff B. Misoprostol to treat missed abortion in the first trimester. IJGO, 2007;99(2); 182–185.
32. Gómez Ponce de León R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. IJGO, 2007; 99( 2):190–193.
33. Tanha F.D., Feizi M., Shariat M. Sublingual versus vaginal misoprostol for the management of missed abortion. J Obstet Gynaecol Res., 2010;36(3):525–32.
34. Machtinger R., Stockheim D., Seidman D.S., Lerner-Geva L., Dor J., Schiff E., Shulman A. Medical treatment with misoprostol for early failure of pregnancies after assisted reproductive technology: a promising treatment option. Fertil Steril., 2009;91(5):1881–5.
35. Davis A.R., Robilotto C.M., Westhoff C.L., Forman S., Zhang J. Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure. Hum Reprod., 2004;19(7):1655–8.
36. Coughlin L.B., Roberts D., Haddad N.G., Long A. Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective? J Obstet Gynaecol., 2004;24(1):69–71.
37. Zhang J., Gilles J.M., Barnhart K. et al. National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med., 2005;353:761–769.
38. Wildschut H., Both M.I., Medema S., Thomee E., Wildhagen M.F., Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;19(1):CD005216, available at: http://www.ncbi.nlm.nih.gov/pubmed/21249669
39. Ngoc N.T., Shochet T., Raghavan S., Blum J., Nga N.T., Minh N.T., Phan V.Q., Winikoff B. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol., 2011;118(3):601–8.
40. Ashok P.W., Templeton A., Wagaarachchi P.T. et al. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception, 2004;69(1):51–58.
41. Milani F., Sharami S.H., Arjmandi S. Comparison of Sublingual and Vaginal Misoprostol for Second-Trimester Pregnancy Terminations. Journal of Family and Reproductive Health. 2014; 8(1): 41–44.
42. Dickinson J.E., Jennings B.G., Doherty D.A. Mifepristone and Oral, Vaginal, or Sublingual Misoprostol for Second-Trimester Abortion: A Randomized Controlled Trial. Obstet. Gynecol. 2014;123(6):1162–1168.
43. Ngo T.D., Park M.H., Shakur H., Free C. Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review. Bull World Health Organ. 2011 ;89(5):360–70.
44. Løkeland M., Iversen O.E., Engeland A., Økland I., Bjørge L. Medical abortion with mifepristone and homeadministration of misoprostol up to 63 days’gestation //Acta Obstet. Gynecol. Scand. 2014;93:647–653.
45. Ngo T.D., Park M.H., Free C. Safety and effectiveness of termination services performed by doctors versus midlevel providers: a systematic review and analysis. Int J Womens Health. 2013;5:9–17.
46. Bracken H., Clark W., Lichtenberg E.S., Schweikert S.M., Tanenhaus J., Barajas A., Alpert L., Winikoff B. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone–misoprostol. BJOG. 2011;118:17–23.
47. Schonberg D., Wang L.F., Bennett A.H., Gold M., Jackson E. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90(5):480–7.
48. El-Baradie S.M., El-Said M.H., Ragab W.S., Elssery K.M., Mahmoud M. Endometrial thickness and serum beta-hCG as predictors of the effectiveness of oral misoprostol in early pregnancy failure. J Obstet Gynaecol Can., 2008; 30(10):877–81.
49. Dikke G.B., Kutueva F.R. Experience of interruption of pregnancy with one tablet of mifepristone (200 mg) in combination with misoprostol in the outpatient practice of the female consultation No. 22 in St. Petersburg. Zemskiy vrach, 2012;4: 25–31 (in Russ.).
50. Wiebe E.R. Use of telemedicine for providing medical abortion. Int J Gynaecol Obstet., 2014;124(2):177–8.
51. Platais I., Tsereteli T., Comendant R., Kurbanbekova D., Winikoff B. Acceptability and feasibility of phone follow-up with a semiquantitative urine pregnancy test after medical abortion in Moldova and Uzbekistan. Contraception, 2015;91(2):178–83.